Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07124117 · ClinicalTrials.gov registry record · Phase 1

A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by OBI Pharma.

Recruiting
Registry status
Phase 1
Development phase
147
Enrollment target
6
Study locations

NCT07124117: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by OBI Pharma.

NCT07124117 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by OBI Pharma. The registered enrollment target is 147 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (23% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07124117, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by OBI Pharma.

RECRUITING
Registry status
Phase 1
Development phase
147 participants
Enrollment target
6
Study locations

Study Summary

This is a 3-part study. Phase 1a (dose escalation) is designed to assess the safety and tolerability and to determine the maximum tolerated dose (MTD) and putative recommended phase 2 dose (RP2D) of study drug as monotherapy. Phase 1b (Cohort Expansion) is intended to further characterize the safety and preliminary antitumor activity of the putative RP2D of OBI-902 in selected tumor types. Phase 2 (Randomized Dose Optimization Cohorts) is intended to determine the optimal RP2D of OBI-902 in selected tumor types, before advancing to larger Phase 3 trials.

Primary Outcome

To assess the safety and tolerability of OBI-902 when administered intravenously to participants with advanced solid tumors

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG OBI-902

Study Locations (6)

Texas

  • The University of Texas MD Anderson Cancer Center - Houston
  • NEXT Oncology - San Antonio

California

  • Scripps Green Hospital - La Jolla

Wenshan

  • Wan Fan Hospital - Taipei

Zhonghe

  • Shuang Ho Hospital - Taipei

Other

  • China Medical University Hospital - Taichung

Trial Details

FieldValue
Enrollment Target 147 participants
Start Date 2025-08-04
Est. Completion 2029-02-08
Phase Phase 1
OBI Pharma

7 total trials

What NCT07124117 shows while recruiting

NCT07124117 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (23% lower).

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which OBI-902 is the first listed.

NCT07124117 lists 6 locations in 5 states (Texas, California, Wenshan).

Frequently Asked Questions

What is clinical trial NCT07124117 about?

NCT07124117 is a clinical study titled "A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors". This is a 3-part study. Phase 1a (dose escalation) is designed to assess the safety and tolerability and to determine the maximum tolerated dose (MTD) and putative recommended phase 2 dose (RP2D) of study drug as monotherapy. Phase 1b (Cohort Expansion) is intended to further characterize the safety...

What is the current status of trial NCT07124117?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 147 participants. The study started on 2025-08-04. Estimated completion is 2029-02-08.

What conditions does trial NCT07124117 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT07124117?

The interventions under investigation include: OBI-902 (DRUG).

Who is sponsoring clinical trial NCT07124117?

This trial is sponsored by OBI Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07124117 being conducted?

This trial has 6 study locations across California, Texas, Wenshan, Zhonghe. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07124117's enrollment target sits among peer trials

147 91st of 189 higher than 99 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04396613 · 147 participants · NA

    Wound Closure Techniques in Primary Spine Surgery

  • NCT04851119 · 147 participants · Phase 1

    Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • NCT05523947 · 147 participants · Phase 1

    Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

  • NCT06121843 · 147 participants · Phase 1

    A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07124117

Source: ClinicalTrials.gov NCT07124117, the US trial registry maintained by the National Library of Medicine. NCT07124117 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.